FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• SOMATULINE DEPOT (LANREOTIDE ACETATE)

Snippet

SUPPL AP for SOMATULINE DEPOT (LANREOTIDE ACETATE)